Realising New Health Technologies

Problems of regulating human stem cells in the USA

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Stem cell technology holds the promise of radically changing medicine through the provision of better disease models; the creation of tissue, cells, and organs for therapeutic uses; and the increased personalisation of healthcare. However, the degree to which any of these developments can be realised in the USA rests upon how effective the regulatory environment is in nurturing the technology to market. This article assesses the regulation in terms of its ability to minimise factors which erode the public interest in developing medical innovations (abuse) and promoting them to the market. This requires an overarching review of patent law (and how it fits with anti-trust and contract law); as well as the general regulation of innovation through ethical review, clinical trials, market authorisation, post-market oversight; government lead regulation of stem cells; and finally incorporating the impact of self-regulation by industry. From this assessment, it becomes possible to appreciate that the optimal system of regulation is reliant upon the gentle tweaking of many factors, rather than the wholesale revision of only a few. It also becomes possible to identify that individual tools of regulation have varying impacts. For example, the patent system may be the most open to abuse by individual companies, but as a regulatory framework it has the most mechanisms for dealing with such abuses. However, the biggest impact upon curtailing abuse derives from the self-regulation of the industry. Conversely, government led regulation is open to abuse from political agendas, but it has the greatest capacity to nurture innovation productively.
Original languageEnglish
Pages (from-to)540-575
Number of pages36
JournalMedical Law Review
Volume20
Issue number4
Early online date6 Apr 2012
DOIs
Publication statusPublished - 1 Dec 2012
Externally publishedYes

Fingerprint

Government Regulation
Biomedical Technology
Industry
Stem Cells
Ethical Review
Technology
abuse
regulation
Aptitude
Therapeutic Uses
Contracts
health
Medicine
market
Clinical Trials
self-regulation
innovation
Delivery of Health Care
patent system
patent law

Cite this

@article{73da0db4387c4c7fb3934c8f5a7447fb,
title = "Realising New Health Technologies: Problems of regulating human stem cells in the USA",
abstract = "Stem cell technology holds the promise of radically changing medicine through the provision of better disease models; the creation of tissue, cells, and organs for therapeutic uses; and the increased personalisation of healthcare. However, the degree to which any of these developments can be realised in the USA rests upon how effective the regulatory environment is in nurturing the technology to market. This article assesses the regulation in terms of its ability to minimise factors which erode the public interest in developing medical innovations (abuse) and promoting them to the market. This requires an overarching review of patent law (and how it fits with anti-trust and contract law); as well as the general regulation of innovation through ethical review, clinical trials, market authorisation, post-market oversight; government lead regulation of stem cells; and finally incorporating the impact of self-regulation by industry. From this assessment, it becomes possible to appreciate that the optimal system of regulation is reliant upon the gentle tweaking of many factors, rather than the wholesale revision of only a few. It also becomes possible to identify that individual tools of regulation have varying impacts. For example, the patent system may be the most open to abuse by individual companies, but as a regulatory framework it has the most mechanisms for dealing with such abuses. However, the biggest impact upon curtailing abuse derives from the self-regulation of the industry. Conversely, government led regulation is open to abuse from political agendas, but it has the greatest capacity to nurture innovation productively.",
keywords = "USA, stem cell, regulation, Biomedicine",
author = "Amanda Warren-Jones",
year = "2012",
month = "12",
day = "1",
doi = "10.1093/medlaw/fws004",
language = "English",
volume = "20",
pages = "540--575",
journal = "Medical Law Review",
issn = "0967-0742",
publisher = "Oxford University Press",
number = "4",

}

Realising New Health Technologies : Problems of regulating human stem cells in the USA. / Warren-Jones, Amanda.

In: Medical Law Review, Vol. 20, No. 4, 01.12.2012, p. 540-575.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Realising New Health Technologies

T2 - Problems of regulating human stem cells in the USA

AU - Warren-Jones, Amanda

PY - 2012/12/1

Y1 - 2012/12/1

N2 - Stem cell technology holds the promise of radically changing medicine through the provision of better disease models; the creation of tissue, cells, and organs for therapeutic uses; and the increased personalisation of healthcare. However, the degree to which any of these developments can be realised in the USA rests upon how effective the regulatory environment is in nurturing the technology to market. This article assesses the regulation in terms of its ability to minimise factors which erode the public interest in developing medical innovations (abuse) and promoting them to the market. This requires an overarching review of patent law (and how it fits with anti-trust and contract law); as well as the general regulation of innovation through ethical review, clinical trials, market authorisation, post-market oversight; government lead regulation of stem cells; and finally incorporating the impact of self-regulation by industry. From this assessment, it becomes possible to appreciate that the optimal system of regulation is reliant upon the gentle tweaking of many factors, rather than the wholesale revision of only a few. It also becomes possible to identify that individual tools of regulation have varying impacts. For example, the patent system may be the most open to abuse by individual companies, but as a regulatory framework it has the most mechanisms for dealing with such abuses. However, the biggest impact upon curtailing abuse derives from the self-regulation of the industry. Conversely, government led regulation is open to abuse from political agendas, but it has the greatest capacity to nurture innovation productively.

AB - Stem cell technology holds the promise of radically changing medicine through the provision of better disease models; the creation of tissue, cells, and organs for therapeutic uses; and the increased personalisation of healthcare. However, the degree to which any of these developments can be realised in the USA rests upon how effective the regulatory environment is in nurturing the technology to market. This article assesses the regulation in terms of its ability to minimise factors which erode the public interest in developing medical innovations (abuse) and promoting them to the market. This requires an overarching review of patent law (and how it fits with anti-trust and contract law); as well as the general regulation of innovation through ethical review, clinical trials, market authorisation, post-market oversight; government lead regulation of stem cells; and finally incorporating the impact of self-regulation by industry. From this assessment, it becomes possible to appreciate that the optimal system of regulation is reliant upon the gentle tweaking of many factors, rather than the wholesale revision of only a few. It also becomes possible to identify that individual tools of regulation have varying impacts. For example, the patent system may be the most open to abuse by individual companies, but as a regulatory framework it has the most mechanisms for dealing with such abuses. However, the biggest impact upon curtailing abuse derives from the self-regulation of the industry. Conversely, government led regulation is open to abuse from political agendas, but it has the greatest capacity to nurture innovation productively.

KW - USA

KW - stem cell

KW - regulation

KW - Biomedicine

U2 - 10.1093/medlaw/fws004

DO - 10.1093/medlaw/fws004

M3 - Article

VL - 20

SP - 540

EP - 575

JO - Medical Law Review

JF - Medical Law Review

SN - 0967-0742

IS - 4

ER -